The Study
Five-year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists.
This study watched a lot of people over five years to see if those who took GLP-1 drugs were more likely to get knee or hip arthritis. It found a link, but it can't prove the medicine caused the arthritis because it didn’t randomly assign people to take it.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
This study looked at whether people with diabetes who take GLP-1 drugs are more likely to get joint problems in their hips or knees over five years.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 553 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1The results suggest GLP-1 drugs may be linked to worse joint issues in diabetics, but not in people without diabetes, which could matter when choosing treatments.
- 2Diabetic patients on GLP-1 drugs had 52% to 78% higher risk of hip or knee arthritis.
- 3They also got more joint injections.
- 4Obese people without diabetes on these drugs did not have higher joint risks.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The Journal of arthroplasty
Year
2024
Authors
Monish S. Lavu, J. Porto, Christian J. Hecht, D. Kaelber, P. Sculco, N. Heckmann, A. Kamath
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.